Symbols / BTTX $0.00 +0.00% Better Therapeutics, Inc.
BTTX Chart
About
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis ,and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
Fundamentals
Scroll to Statements| Market Cap | 5.45K | Enterprise Value | 7.71M | Income | -31.57M | Sales | — | Book/sh | -0.24 | Cash/sh | 0.14 |
| Dividend Yield | — | Payout | 0.00% | Employees | 54 | IPO | — | P/E | — | Forward P/E | -0.00 |
| PEG | — | P/S | — | P/B | -0.00 | P/C | — | EV/EBITDA | -0.26 | EV/Sales | — |
| Quick Ratio | 0.52 | Current Ratio | 0.57 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -1.10 | EPS next Y | -1.00 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2023-11-09 | ROA | -95.05% | ROE | — | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 54.52M | Shs Float | 30.54M | Short Float | 6.21% |
| Short Ratio | 0.94 | Short Interest | — | 52W High | 0.00 | 52W Low | 0.00 | Beta | -40.01 | Avg Volume | 3.44K |
| Volume | 500.00 | Target Price | — | Recom | None | Prev Close | $0.00 | Price | $0.00 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-5.14
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-08-10 | main | Lake Street | Buy → Buy | $3 |
| 2023-08-10 | reit | Chardan Capital | Buy → Buy | $9 |
| 2023-04-14 | main | Lake Street | — → Buy | $5 |
| 2023-03-31 | main | Chardan Capital | — → Buy | $9 |
| 2022-11-15 | main | Chardan Capital | — → Buy | $14 |
| 2022-07-29 | main | Chardan Capital | — → Buy | $17 |
| 2022-03-16 | main | Chardan Capital | — → Buy | $18 |
| 2021-11-24 | init | Chardan Capital | — → Buy | $17 |
| 2021-11-10 | init | Cowen & Co. | — → Outperform | — |
- BTTX Stock Price, News & Analysis - Stock Titan Fri, 25 Apr 2025 00
- Better Therapeutics Stock Price Forecast. Should You Buy BTTX? - StockInvest.us ue, 09 Nov 2021 06
- BTTX Stock Chart | BETTER THERAPEUTICS INC (NASDAQ:BTTX) - ChartMill Fri, 15 Mar 2024 07
- Better Therapeutics Shutters Operations, Terminates Employees, NASDAQ Delisting - HIT Consultant hu, 14 Mar 2024 07
- Better Therapeutics CEO Discusses Future on Bloomberg TV - TipRanks Mon, 04 Mar 2024 08
- Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq - Business Wire hu, 14 Mar 2024 07
- BETTER THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K) - marketscreener.com hu, 11 May 2023 07
- 3 Penny Stocks That Have Huge Catalysts Ahead - InvestorPlace Mon, 27 Jun 2022 07
- Georgianna Maule Ffinch 2015 Trust Net Worth (2026) - GuruFocus Sat, 13 May 2023 05
- RBSH Stock Price, News & Analysis - Stock Titan ue, 12 Oct 2021 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
| Operating Expense |
|
38.26
+25.20%
|
30.56
|
| Research And Development |
|
16.44
-15.41%
|
19.44
|
| Selling General And Administration |
|
21.82
+96.17%
|
11.12
|
| Selling And Marketing Expense |
|
6.98
+198.76%
|
2.34
|
| General And Administrative Expense |
|
14.84
+68.90%
|
8.79
|
| Other Gand A |
|
14.84
+68.90%
|
8.79
|
| Total Expenses |
|
38.26
+25.20%
|
30.56
|
| Operating Income |
|
-38.26
-25.20%
|
-30.56
|
| Total Operating Income As Reported |
|
-38.26
-25.20%
|
-30.56
|
| EBITDA |
|
-35.53
+8.15%
|
-38.68
|
| Normalized EBITDA |
|
-35.53
-22.78%
|
-28.94
|
| Reconciled Depreciation |
|
2.73
+68.56%
|
1.62
|
| EBIT |
|
-38.26
+5.06%
|
-40.30
|
| Total Unusual Items |
|
0.00
+100.00%
|
-9.74
|
| Total Unusual Items Excluding Goodwill |
|
0.00
+100.00%
|
-9.74
|
| Special Income Charges |
|
0.00
-100.00%
|
0.65
|
| Other Special Charges |
|
—
|
-0.65
|
| Net Income |
|
-39.76
+1.43%
|
-40.34
|
| Pretax Income |
|
-39.75
+1.82%
|
-40.49
|
| Net Non Operating Interest Income Expense |
|
-1.49
-705.95%
|
-0.18
|
| Interest Expense Non Operating |
|
1.49
+705.95%
|
0.18
|
| Net Interest Income |
|
-1.49
-705.95%
|
-0.18
|
| Interest Expense |
|
1.49
+705.95%
|
0.18
|
| Other Income Expense |
|
—
|
-9.74
|
| Gain On Sale Of Security |
|
—
|
-10.39
|
| Tax Provision |
|
0.01
+104.58%
|
-0.15
|
| Tax Rate For Calcs |
|
0.00
+5457.03%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
+100.00%
|
-0.04
|
| Net Income Including Noncontrolling Interests |
|
-39.76
+1.43%
|
-40.34
|
| Net Income From Continuing Operation Net Minority Interest |
|
-39.76
+1.43%
|
-40.34
|
| Net Income From Continuing And Discontinued Operation |
|
-39.76
+1.43%
|
-40.34
|
| Net Income Continuous Operations |
|
-39.76
+1.43%
|
-40.34
|
| Normalized Income |
|
-39.76
-29.81%
|
-30.63
|
| Net Income Common Stockholders |
|
-39.76
+1.43%
|
-40.34
|
| Diluted EPS |
|
-1.69
+45.66%
|
-3.11
|
| Basic EPS |
|
-1.69
+45.66%
|
-3.11
|
| Basic Average Shares |
|
23.56
+81.46%
|
12.98
|
| Diluted Average Shares |
|
23.56
+81.46%
|
12.98
|
| Diluted NI Availto Com Stockholders |
|
-39.76
+1.43%
|
-40.34
|
| Line Item | Trend | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Total Assets |
|
22.94
-54.98%
|
50.96
|
| Current Assets |
|
18.45
-59.24%
|
45.25
|
| Cash Cash Equivalents And Short Term Investments |
|
15.74
-61.20%
|
40.57
|
| Cash And Cash Equivalents |
|
15.74
-61.20%
|
40.57
|
| Cash Financial |
|
—
|
40.57
|
| Prepaid Assets |
|
2.50
-43.39%
|
4.41
|
| Other Current Assets |
|
0.21
-23.91%
|
0.28
|
| Total Non Current Assets |
|
4.50
-21.20%
|
5.71
|
| Net PPE |
|
0.12
+47.56%
|
0.08
|
| Gross PPE |
|
0.18
-42.58%
|
0.31
|
| Accumulated Depreciation |
|
-0.06
+75.00%
|
-0.23
|
| Machinery Furniture Equipment |
|
0.18
-42.58%
|
0.31
|
| Goodwill And Other Intangible Assets |
|
3.89
-23.42%
|
5.08
|
| Other Intangible Assets |
|
3.89
-23.42%
|
5.08
|
| Other Non Current Assets |
|
0.49
-10.95%
|
0.55
|
| Total Liabilities Net Minority Interest |
|
23.84
+67.45%
|
14.24
|
| Current Liabilities |
|
13.49
+185.10%
|
4.73
|
| Payables And Accrued Expenses |
|
8.96
+89.35%
|
4.73
|
| Payables |
|
3.04
+99.28%
|
1.52
|
| Accounts Payable |
|
3.04
+99.28%
|
1.52
|
| Current Accrued Expenses |
|
5.93
+84.64%
|
3.21
|
| Current Debt And Capital Lease Obligation |
|
4.53
|
—
|
| Current Debt |
|
4.53
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
10.35
+8.87%
|
9.51
|
| Long Term Debt And Capital Lease Obligation |
|
10.35
+8.87%
|
9.51
|
| Long Term Debt |
|
10.35
+8.87%
|
9.51
|
| Non Current Deferred Liabilities |
|
—
|
0.00
|
| Non Current Deferred Taxes Liabilities |
|
—
|
0.00
|
| Stockholders Equity |
|
-0.90
-102.45%
|
36.72
|
| Common Stock Equity |
|
-0.90
-102.45%
|
36.72
|
| Capital Stock |
|
0.00
+0.00%
|
0.00
|
| Common Stock |
|
0.00
+0.00%
|
0.00
|
| Share Issued |
|
23.85
+1.05%
|
23.60
|
| Ordinary Shares Number |
|
23.85
+1.05%
|
23.60
|
| Additional Paid In Capital |
|
110.60
+1.97%
|
108.46
|
| Retained Earnings |
|
-111.50
-55.42%
|
-71.74
|
| Total Equity Gross Minority Interest |
|
-0.90
-102.45%
|
36.72
|
| Total Capitalization |
|
9.45
-79.56%
|
46.23
|
| Working Capital |
|
4.95
-87.78%
|
40.52
|
| Invested Capital |
|
13.98
-69.75%
|
46.23
|
| Total Debt |
|
14.88
+56.55%
|
9.51
|
| Net Tangible Assets |
|
-4.79
-115.13%
|
31.64
|
| Tangible Book Value |
|
-4.79
-115.13%
|
31.64
|
| Interest Payable |
|
0.17
+118.18%
|
0.08
|
| Line Item | Trend | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Operating Cash Flow |
|
-28.93
+6.13%
|
-30.82
|
| Cash Flow From Continuing Operating Activities |
|
-28.93
+6.13%
|
-30.82
|
| Net Income From Continuing Operations |
|
-39.76
+1.43%
|
-40.34
|
| Depreciation Amortization Depletion |
|
2.73
+68.56%
|
1.62
|
| Depreciation And Amortization |
|
2.73
+68.56%
|
1.62
|
| Other Non Cash Items |
|
—
|
9.74
|
| Stock Based Compensation |
|
1.82
+182.35%
|
0.65
|
| Asset Impairment Charge |
|
0.01
|
0.00
|
| Deferred Tax |
|
0.00
+100.00%
|
-0.15
|
| Deferred Income Tax |
|
0.00
+100.00%
|
-0.15
|
| Operating Gains Losses |
|
—
|
-0.65
|
| Change In Working Capital |
|
6.27
+367.98%
|
-2.34
|
| Change In Prepaid Assets |
|
2.04
+144.20%
|
-4.61
|
| Change In Payables And Accrued Expense |
|
4.23
+85.97%
|
2.27
|
| Change In Accrued Expense |
|
2.72
+114.78%
|
1.26
|
| Change In Payable |
|
1.51
+49.85%
|
1.01
|
| Change In Account Payable |
|
1.51
+49.85%
|
1.01
|
| Investing Cash Flow |
|
-1.18
-10.18%
|
-1.07
|
| Cash Flow From Continuing Investing Activities |
|
-1.18
-10.18%
|
-1.07
|
| Net PPE Purchase And Sale |
|
-0.11
-92.73%
|
-0.06
|
| Purchase Of PPE |
|
-0.11
-92.73%
|
-0.06
|
| Capital Expenditure |
|
-1.18
-10.18%
|
-1.07
|
| Capital Expenditure Reported |
|
-1.07
-5.71%
|
-1.02
|
| Net Intangibles Purchase And Sale |
|
—
|
-1.02
|
| Purchase Of Intangibles |
|
—
|
-1.02
|
| Financing Cash Flow |
|
5.28
-92.69%
|
72.33
|
| Cash Flow From Continuing Financing Activities |
|
5.28
-92.69%
|
72.33
|
| Net Issuance Payments Of Debt |
|
5.00
-82.56%
|
28.68
|
| Issuance Of Debt |
|
5.00
-82.56%
|
28.68
|
| Long Term Debt Issuance |
|
5.00
-82.56%
|
28.68
|
| Net Long Term Debt Issuance |
|
5.00
-82.56%
|
28.68
|
| Proceeds From Stock Option Exercised |
|
0.28
-99.52%
|
59.05
|
| Net Other Financing Charges |
|
—
|
-15.39
|
| Changes In Cash |
|
-24.83
-161.39%
|
40.44
|
| Beginning Cash Position |
|
40.57
+32880.49%
|
0.12
|
| End Cash Position |
|
15.74
-61.20%
|
40.57
|
| Free Cash Flow |
|
-30.11
+5.58%
|
-31.89
|
| Interest Paid Supplemental Data |
|
1.32
+1458.82%
|
0.09
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|